Globally, considering a 1.5 million annual increase in hepatitis B carriers, adopting TAF instead of ETV could result in substantial annual savings surpassing NT$2.6 billion (approximately US$88 million). The gene discussed is PPIB; the disease is hepatitis A virus infection.